US · Healthcare · Biotechnology
EPS came in at -0.32 against a street estimate of -0.36 — a beat of 11.1%.
Analysts rate Novavax Inc a buy (5 buy, 1 hold, 3 sell out of 9) with an average price target of $14.00.
| Fund | Stake |
|---|---|
| Shah Capital Management | 8.59% |
| BlackRock Inc | 7.79% |
| State Street Corp | 5.44% |
| Vanguard Portfolio Management, LLC | 4.34% |
| Vanguard Capital Management, LLC | 4.32% |
| Sanofi | 4.17% |
| Bank of America Corp | 4.02% |
| D. E. Shaw & Co LP | 3.43% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 NOVAVAX, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Loss (6 months): $62.9 million vs. Net Income $625.2 million (prior year) • Net Loss (Q2 | 2026-08-06 |
| Results announced · Q3 2026 NOVAVAX Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $57 million – down 76% from $239 million in Q2 2025 • Q2 2026 Ne | 2026-08-06 |
| Shareholder vote results · Q2 2026 NOVAVAX, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting Date: June 18, 2026 • Outstanding Common Stock (Record Date April 23, 2026): 164, | 2026-06-23 |
| Quarterly report · Q1 2026 NOVAVAX, INC. - Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q1 2026 Net Loss: $9.5 million (vs. Q1 2025 net income of $518.6 million) — | 2026-05-06 |
| Results announced · Q2 2026 NOVAVAX Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $140 million in Q1 2026 (down 79% from $667 million in Q1 2025) • Net lo | 2026-05-06 |
| Proxy statement · Q2 2026 NOVAVAX, INC. (NVAX) 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION • John C. Jacobs (President and CEO) Total Compensation: The document does not pr | 2026-04-27 |
| Annual report FY2025 NOVAVAX, INC. – 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $1,018,000,000 • Outstanding | 2026-02-26 |
| Results announced · Q1 2026 NOVAVAX, INC. – Q4 2025 & FULL YEAR 2025 EARNINGS SUMMARY HEADLINE NUMBERS • Total Revenue FY 2025: $1,123 million (65% increase vs. FY 2024's $682 | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raised full-year 2026 revenue framework and improved expense guidance Novavax reported Q2 2026 revenue of $57 million, down 76% from $239 million in Q2 2025, but the decline was expected due to one-time milestone payments in the prior year. The company raised | 2026-08-06 |
| License and option agreement for adjuvant technology with milestone payments Novavax signed a licensing deal with pharmaceutical giant Pfizer on January 15, 2026, to use Novavax's Matrix-M adjuvant technology (a vaccine booster) in Pfizer's vaccine products. Here's w | 2026-01-20 |
| FDA approves marketing authorization transfer of Nuvaxovid to Sanofi Novavax announced that the FDA approved transferring the marketing authorization for its COVID-19 vaccine Nuvaxovid from Novavax to Sanofi Pasteur on November 3, 2025. This approval triggere | 2025-11-04 |
| European Commission approves Nuvaxovid marketing authorization transfer to Sanofi Novavax announced that the European Commission approved transferring its Nuvaxovid COVID-19 vaccine marketing authorization from Novavax's subsidiary to Sanofi Winthrop Industrie on October | 2025-10-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novavax Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.